Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10032751HBVENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS20002957HPVENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS20031069HPVENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS20030899HPVENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS44021579HTLV-1ENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS44024241HTLV-1ENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS44014377HTLV-1ENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TVIS44029002HTLV-1ENSG00000011677.13protein_codingGABRA3NoNo2556P34903
TCGA Plot Options
Drug Information
GeneGABRA3
DrugBank IDDB01496
Drug NameDihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione
Target IDBE0000523
UniProt IDP34903
Regulation Typepotentiator
PubMed IDs11264449; 10209232
CitationsYamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51.@@Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.
GroupsExperimental; Illicit
Direct ClassificationTrifluoromethylbenzenes
SMILESFC(F)(F)C1=CC=CC=C1C1=CC=C(CC2C(=O)NC(=S)NC2=O)O1
Pathways
PharmGKB
ChEMBL